Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentuximab injection plus paclitaxel in advanced gastric or gastroesophageal junction adenocarcinoma
CTR20191463Phase 2Completed
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gentuximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Nov 2019; status: completed.
02
Drugs
gentuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20191463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191463.